Phase I/II Study of PDR001 in Patients With Advanced Malignancies (Novartis Pharmaceuticals): Investigators will look at the safety, tolerability, and antitumor activity of a new PD-L1 checkpoint inhibitor.
Explore This Issue
September 2016Pembrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (Royal Marsden NHS Foundation Trust, United Kingdom): This study aims to establish whether the combination of pembrolizumab and conventional cisplatin-based chemoradiotherapy is tolerable and results in acceptable levels of toxicity in patients with stage IV head and neck cancer.